ABU DHABI DEPARTMENT OF HEALTH HAS SIGNED AN AGREEMENT TO ESTABLISH A CLINICAL RESEARCH HUB AND NOVEL TREATMENTS

  • 17/06/2022

Abu Dhabi: The Department of Health – Abu Dhabi (DoH), the emirate's healthcare authority, has inked a strategic collaboration agreement with the US pharmaceutical giant Johnson & Johnson to support the emirate's ambition of becoming a regional hub for clinical research and data development.


The new strategic partnership, inked with Johnson & Johnson Middle East FZ-LLC, aims to deliver novel treatments and breakthrough solutions to the UAE and the MENA region, as well as exchange expertise and experiences in the healthcare sector.

The Abu Dhabi Health Department and the US company's Middle East unit will investigate key prospective areas of interest in order to build short and long-term projects in the collection of data and real-world evidence (RWE). 

The Declaration of Collaboration was signed by Dr. Asma Al Mannaei, executive director, research and innovation centre at DoH, and Jamie Phares, managing director of Janssen GCC, a Johnson and Johnson company.

The strategic pact with Johnson and Johnson, signed during the BIO International Convention 2022 held in San Diego, California on June 13-16, is line with Abu Dhabi’s initiatives to seek lead research groups supported by global partners to establish the strength and sustainability of the healthcare sector as well as provide quality care to patients in the emirate.

An Abu Dhabi delegation is participating at the BIO International Convention 2022 to showcase the domestic growth and economic development of the emirate’s biotechnology industry.

Related News